-
公开(公告)号:US11084803B2
公开(公告)日:2021-08-10
申请号:US16231324
申请日:2018-12-21
发明人: Li-Huei Tsai , Ling Pan , Stephen J. Haggarty , Debasis Patnaik
IPC分类号: C07D405/12 , C07D409/12 , C07C217/58 , C07D411/12 , C07D307/40 , C07C219/28 , C07D307/52 , C07D487/04
摘要: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
-
公开(公告)号:US20160280693A1
公开(公告)日:2016-09-29
申请号:US14834587
申请日:2015-08-25
申请人: Massachusetts Institute of Technology , The General Hospital Corporation d/b/a Massachusetts General Hospital
发明人: Li-Huei Tsai , Ling Pan , Stephen J. Haggarty , Debasis Patnaik
IPC分类号: C07D405/12
CPC分类号: C07D405/12 , C07C217/58 , C07C219/28 , C07D307/40 , C07D307/52 , C07D409/12 , C07D411/12 , C07D487/04
摘要: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
-
公开(公告)号:US11639325B2
公开(公告)日:2023-05-02
申请号:US17116427
申请日:2020-12-09
IPC分类号: C07C49/83 , A61K9/00 , A61K45/06 , A61K31/12 , C07C49/84 , C07C215/20 , C07C69/017 , A61P25/28 , C07C65/34
摘要: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
-
公开(公告)号:US20190211000A1
公开(公告)日:2019-07-11
申请号:US16231324
申请日:2018-12-21
申请人: Massachusetts Institute of Technology , The General Hospital Corporation d/b/a Massachusetts General Hospital
发明人: Li-Huei Tsai , Ling Pan , Stephen J. Haggarty , Debasis Patnaik
IPC分类号: C07D405/12 , C07D307/40 , C07D411/12 , C07C217/58 , C07C219/28 , C07D409/12 , C07D307/52 , C07D487/04
CPC分类号: C07D405/12 , C07C217/58 , C07C219/28 , C07D307/40 , C07D307/52 , C07D409/12 , C07D411/12 , C07D487/04
摘要: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
-
公开(公告)号:US20220064151A1
公开(公告)日:2022-03-03
申请号:US17397752
申请日:2021-08-09
申请人: Massachusetts Institute of Technology , The General Hospital Corporation d/b/a Massachusetts General Hospital
发明人: Li-Huei Tsai , Ling Pan , Stephen J. Haggarty , Debasis Patnaik
IPC分类号: C07D405/12 , C07D307/52 , C07D411/12 , C07D307/40 , C07C217/58 , C07D487/04 , C07C219/28 , C07D409/12
摘要: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
-
公开(公告)号:US11180438B2
公开(公告)日:2021-11-23
申请号:US16010030
申请日:2018-06-15
IPC分类号: A61K31/12 , C07C49/83 , A61K9/00 , A61K45/06 , C07C49/84 , C07C215/20 , C07C69/017 , A61P25/28 , C07C65/34
摘要: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
-
公开(公告)号:US20210171429A1
公开(公告)日:2021-06-10
申请号:US17116427
申请日:2020-12-09
申请人: Massachusetts Institute of Technology , The General Hospital Corporation d/b/a Massachusetts General Hospital
IPC分类号: C07C49/83 , C07C49/84 , A61K9/00 , A61K45/06 , C07C69/017 , A61K31/12 , C07C215/20 , A61P25/28 , C07C65/34
摘要: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.
-
公开(公告)号:US10167277B2
公开(公告)日:2019-01-01
申请号:US14834587
申请日:2015-08-25
发明人: Li-Huei Tsai , Ling Pan , Stephen J. Haggarty , Debasis Patnaik
IPC分类号: C07D405/12 , C07D409/12 , C07D411/12 , C07C219/28 , C07D307/52 , C07D487/04 , C07C217/58 , C07D307/40
摘要: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
-
-
-
-
-
-
-